NDA 210491 · Vertex Pharms INC
Symdeko (Copackaged)
Ivacaftor, Ivacaftor, Tezacaftor · Oral
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Mar 17, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Feb 12, 2018
Approved uses
3
Original approval plus efficacy supplements
Registered trials
136
60 Phase 3, 11 recruiting
FAERS reports
5,288
3,301 serious, 74 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 21, 2026.
SYMDEKO is indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence [see Clinical Pharmacology (12.1) and Clinical Studies (14) ] . If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use. SYMDEKO is a combination of tezacaftor and ivacaftor, indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence. ( 12.1 , 14 ) If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use. ( 1 )
Mechanism: Tezacaftor facilitates the cellular processing and trafficking of select mutant forms of CFTR (including F508del-CFTR) to increase the amount of mature CFTR protein delivered to the cell surface. Ivacaftor is a CFTR potentiator that facilitates increased chloride transport by potentiating the channel-open probability (or gating) of the CFTR protein at the cell surface. For ivacaftor to function CFTR protein must be present at the cell surface. Ivacaftor can potentiate the CFTR protein delivered to the cell surface by tezacaftor, leading to a further enhancement of chloride transport than...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 21, 2020 Supplement 7 · Efficacy · priority review OrphanLetterLabel
- Jun 21, 2019 Supplement 3 · Efficacy · priority review OrphanLetterLabel
- Feb 12, 2018 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelBreakthrough therapyOrphanLabelLetterReview
2 products under this application
- SYMDEKO (COPACKAGED) · IVACAFTOR 150MG; IVACAFTOR, TEZACAFTOR 150MG, 100MG · TABLET, ORAL · Prescription
- SYMDEKO (COPACKAGED) · IVACAFTOR 75MG; IVACAFTOR, TEZACAFTOR 75MG, 50MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ivacaftor" as an intervention, any sponsor and status, largest first.
- A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic FibrosisPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT01931839 · 1,164 participants · Start Oct 2013 · Primary completion Apr 2016
Drug: Lumacaftor Plus Ivacaftor Combination; Ivacaftor · For: Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Sites: Birmingham, Alabama; Anchorage, Alaska; Tucson, Arizona · 166 sites in all
- A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR MutationPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT02565914 · 1,131 participants · Start Aug 2015 · Primary completion May 2019
Drug: TEZ/IVA; IVA · For: Cystic Fibrosis
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 154 sites in all
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05076149 · 597 participants · Start Oct 27, 2021 · Primary completion May 18, 2023
Drug: VX-121/TEZ/D-IVA; ELX/TEZ/IVA and 4 more · For: Cystic Fibrosis
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 170 sites in all
- A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR MutationPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT01807949 · 563 participants · Start Apr 2013 · Primary completion Apr 2014
Drug: Placebo; Lumacaftor Plus Ivacaftor Combination and 1 more · For: Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Sites: Oakland, California; Sacramento, California; Aurora, Colorado · 82 sites in all
- A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR MutationPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT01807923 · 559 participants · Start May 2013 · Primary completion Apr 2014
Drug: Lumacaftor Plus Ivacaftor Combination; Ivacaftor and 1 more · For: Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Sites: Birmingham, Alabama; Anchorage, Alaska; Tucson, Arizona · 89 sites in all
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With IvacaftorPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT02347657 · 510 participants · Start Jan 2015 · Primary completion Jan 20, 2017
Drug: VX-661 Plus Ivacaftor Combination; Ivacaftor and 2 more · For: Cystic Fibrosis
Sites: Little Rock, Arkansas; Long Beach, California; Denver, Colorado · 74 sites in all
- A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination TherapyPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT03525574 · 507 participants · Start Oct 9, 2018 · Primary completion Jan 9, 2023
Drug: ELX/TEZ/IVA; IVA · For: Cystic Fibrosis
Sites: Tucson, Arizona; Little Rock, Arkansas; Long Beach, California · 110 sites in all
- A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination TherapyPivotal-lookingTerminated
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT03447262 · 484 participants · Start Jul 13, 2018 · Primary completion Sep 9, 2020
Drug: VX-659/TEZ/IVA; IVA · For: Cystic Fibrosis
Sites: Birmingham, Alabama; Palo Alto, California; Aurora, Colorado · 100 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- infective pulmonary exacerbation of cystic fibrosis1,183
- hospitalisation459
- infection352
- cystic fibrosis288
- pneumonia286
- headache214
- cough183
- cystic fibrosis respiratory infection suppression168
- pulmonary function test decreased144
- nausea140
- dyspnoea135
- haemoptysis132
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 1,201 |
| 2019 | 3,045 |
| 2020 | 801 |
| 2021 | 88 |
| 2022 | 38 |
| 2023 | 39 |
| 2024 | 39 |
| 2025 | 29 |
| 2026 | 8 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
Middleton PG, Mall MA, Devínek P, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Multicenter Study
- Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes.
Barry PJ, Mall MA, Álvarez A, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
- The clinical effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) for people with CF without a F508del variant: A systematic review and meta-analysis.
Lupas D, Chou FY, Hakani MAA, et al. · J Cyst Fibros 2024 · Systematic Review, Meta-Analysis
- Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.
Keating C, Yonker LM, Vermeulen F, et al. · Lancet Respir Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Heijerman HGM, McKone EF, Downey DG, et al. · Lancet 2019 · Clinical Trial, Phase III, Randomized Controlled Trial
- A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.
Ramsey BW, Davies J, McElvaney NG, et al. · N Engl J Med 2011 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Vertex Pharmaceuticals
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.